

Newsletter

Fifth Issue - April 2025

Welcome to the new issue of the METHYLOMIC Project Newsletter!

We are excited to share updates on our progress with all our stakeholders. This newsletter will be released quarterly, aiming to keep everyone informed about the significant developments and achievements within our consortium.

We hope you enjoy this edition and wish you a happy Easter!



The METHYLOMIC project has officially started OMICROHN and EPIPSORA clinical trials! These groundbreaking studies aim to explore the use of epigenetic markers to improve treatment decisions in the context of Crohn's disease, Psoriasis, and Rheumatoid Arthritis.

OMICROHN Trial

We are thrilled to announce that the OMICROHN trial has been officially begun with the recruitment of the first patient in the Netherlands!

We are excited to go further with the recruitment of patients across all participating sites. Meanwhile, our team is working hard to get trial approvals by regulatory authorities in Italy, Slovenia and Hungary. We are confident that we will soon be fully operational across Europe.

If you want to know more about this study, visit our webpage or EFCCA's webpage (the European Federation of Crohn's & Ulcerative Colitis Associations).

EPIPSORA trial

We are equally excited to share that the EPIPSORA trial is now well underway at all active sites in Portugal, the Netherlands, and Belgium, with over 50 patients already in the trial. We are making great strides in advancing this groundbreaking research!

METHYLOMIC Podcasts

We are almost ready to release new episodes of the METHYLOMIC podcast series and insightful interviews with experts, partners and patients. Don't miss out — visit our website and follow us on social media for all the latest updates and exciting news

Engage with us

We encourage all our readers to visit the METHYLOMIC website and follow our updates on social media. Sharing our content helps support our mission and spread the word about our groundbreaking work in the field of medical research.

We look forward to keeping you updated on the progress of these trials and the next steps in our project!

We thank all our partners and collaborators for their continued support and dedication to the METHYLOMIC project. Together, we are paving the way for more personalized and effective care for patients.

